Cash Flow Statement
Growth Metrics

Anika Therapeutics (ANIK) Depreciation & Amortization (CF) (2016 - 2026)

Anika Therapeutics has reported Depreciation & Amortization (CF) over the past 17 years, most recently at $1.4 million for Q1 2026.

  • Quarterly Depreciation & Amortization (CF) rose 1.74% to $1.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $5.4 million through Mar 2026, down 17.4% year-over-year, with the annual reading at $5.4 million for FY2025, 21.96% down from the prior year.
  • Depreciation & Amortization (CF) was $1.4 million for Q1 2026 at Anika Therapeutics, up from $1.3 million in the prior quarter.
  • Over five years, Depreciation & Amortization (CF) peaked at $1.9 million in Q3 2024 and troughed at $1.3 million in Q2 2025.
  • The 5-year median for Depreciation & Amortization (CF) is $1.6 million (2023), against an average of $1.6 million.
  • Year-over-year, Depreciation & Amortization (CF) rose 16.54% in 2024 and then decreased 26.01% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $1.7 million in 2022, then decreased by 5.35% to $1.6 million in 2023, then decreased by 4.18% to $1.6 million in 2024, then fell by 15.51% to $1.3 million in 2025, then rose by 6.75% to $1.4 million in 2026.
  • Per Business Quant, the three most recent readings for ANIK's Depreciation & Amortization (CF) are $1.4 million (Q1 2026), $1.3 million (Q4 2025), and $1.4 million (Q3 2025).